Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Dezember 2010 16:19 ET | Quelle: Myrexis, Inc.

Myrexis Initiates Comparative-Arm Phase 2 Study of Azixa(TM) for the Front-Line Treatment of Glioblastoma Multiforme

SALT LAKE CITY, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
19. November 2010 09:00 ET | Quelle: Myrexis, Inc.

Myrexis Reports Anti-Tumor Activity in a Subset of Patients From Ongoing Phase 2 Azixa(TM) Study in Recurrent Glioblastoma Multiforme at Society for Neuro-Oncology

SALT LAKE CITY, Nov. 19, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
18. November 2010 09:20 ET | Quelle: Myrexis, Inc.

Myrexis to Present at Piper Jaffray Health Care Conference

SALT LAKE CITY, Nov. 18, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
17. November 2010 08:00 ET | Quelle: Myrexis, Inc.

Myrexis Presents Data on Cancer Metabolism Inhibitor at 22nd EORTC/NCI/AACR Symposium

SALT LAKE CITY, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
09. November 2010 16:21 ET | Quelle: Myrexis, Inc.

Myrexis Reports First Quarter Fiscal 2011 Financial Results

AzixaTM Two-Arm Phase 2b Study in Glioblastoma to Begin by Calendar Year-End Received ~$1.2M Section 48D Tax Grant Conference Call Today at 4:30pm EST Upcoming Events Initiate two-arm...
08. November 2010 07:55 ET | Quelle: Myrexis, Inc.

Myrexis Presents Oral Anti-Interferon Data at American College of Rheumatology/Association of Rheumatology Health Professionals

SALT LAKE CITY, Nov. 8, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
28. Oktober 2010 09:15 ET | Quelle: Myrexis, Inc.

Myrexis to Hold Conference Call to Discuss Fiscal First Quarter 2011 Financial Results and Azixa(TM) Phase 2b Study Plans

SALT LAKE CITY, Oct. 28, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
21. Oktober 2010 14:38 ET | Quelle: Myrexis, Inc.

Myrexis to Present Updated Results From Ongoing Phase 2 Azixa(TM) Study in Glioblastoma Multiforme at Society for Neuro-Oncology

SALT LAKE CITY, Oct. 21, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
06. Oktober 2010 14:54 ET | Quelle: Myrexis, Inc.

Myrexis to Present Oral Anti-Interferon Program at American College of Rheumatology/Association of Rheumatology Health Professionals

SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
20. September 2010 07:00 ET | Quelle: Myrexis, Inc.

Myrexis Presents Key Findings From Its Cancer Metabolism Inhibitor, MPC-9528

SALT LAKE CITY, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...

Vorherige Seite

Nächste Seite